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Abstract
Background: Liver disease is a major cause of death worldwide. Orthotropic liver transplantation (OLT) represents
the only effective treatment for patients with liver failure, but the increasing demand for organs is unfortunately so
great that its application is limited. Hepatocyte transplantation is a promising alternative to OLT for the treatment of
some liver-based metabolic disorders or acute liver failure. Unfortunately, the lack of donor livers also makes it
difficult to obtain enough viable hepatocytes for hepatocyte-based therapies. Currently, a fundamental solution to
this key problem is still lacking. Here we show a novel non-transgenic protocol that facilitates the rapid generation
of functional induced hepatocytes (iHeps) from human adipose-derived stem cells (hADSCs), providing a source of
available cells for autologous hepatocytes to treat liver disease.
Methods: We used collagenase digestion to isolate hADSCs. The surface marker was detected by flow cytometry.
The multipotential differentiation potency was detected by induction into adipocytes, osteocytes, and
chondrocytes. Passage 3–7 hADSCs were induced into iHeps using an induction culture system composed of small
molecule compounds and cell factors.
Results: Primary cultured hADSCs presented a fusiform or polygon appearance that became fibroblast-like after
passage 3. More than 95 % of the cells expressed the mesenchymal cell markers CD29, CD44, CD166, CD105, and
CD90. hADSCs possessed multipotential differentiation towards adipocytes, osteocytes, and chondrocytes. We
rapidly induced hADSCs into iHeps within 10 days in vitro; the cellular morphology changed from fusiform to
close-connected cubiform, which was similar to hepatocytes. After induction, most of the iHeps co-expressed
albumin and alpha-1 antitrypsin; they also expressed mature hepatocyte special genes and achieved the basic
functions of hepatocyte. Moreover, iHep transplantation could improve the liver function of acute liver-injured NPG
mice and prolong life.
Conclusions: We isolated highly purified hADSCs and rapidly induced them into functional hepatocyte-like cells
within 10 days. These results provide a source of available cells for autologous hepatocytes to treat liver disease.
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Background
The liver is the largest internal organ in the human body
and the main site of drug metabolism and its resulting
toxicity. Liver diseases are crucial causes of death world-
wide. Orthotropic liver transplantation (OLT) represents
the only effective treatment for patients with liver fail-
ure, but the increasing demand for organs is unfortu-
nately so great that many patients die while awaiting
transplantation [1]. Hepatocyte transplantation has been
proposed as an alternative to whole-organ transplant-
ation to support many forms of hepatic insufficiency.
Unfortunately, the lack of donor livers also makes it
difficult to obtain enough viable hepatocytes for
hepatocyte-based therapies. To solve this dilemma, novel
strategies for generating ample hepatocytes are in high
demand.
Mesenchymal stem cells (MSCs) have become a prom-
inent resource for regenerative medicine as readily avail-
able cells, which can be obtained from different sources
such as bone marrow [2], umbilical cord blood [3],
amniotic fluid [4], scalp tissue [5], placenta [6], or adi-
pose tissue [7] of the human body. These cells show
a multipotentiality and semi-infinite proliferation ability.
In particular, adipose-derived stem cells (ADSCs) are rec-
ognized as one of the most promising MSCs identified
thus far since adipose tissue is ubiquitous and easily ob-
tained in large quantities with little donor site morbidity
or patient discomfort [8–13]. Furthermore, recent
research has revealed that the use of ADSCs in regenera-
tive medicine is not limited to mesodermal tissue but
extends to both ectodermal and endodermal tissues and
organs, although ADSCs originate from mesodermal line-
ages [14, 15].
Here, we describe the isolation of MSCs from human
abdominal adipose tissue and their differentiation into
hepatocyte-like cells (induced hepatocytes (iHeps)) in
vitro using selective cell factors and small molecule
compounds. Post-transplantation of hepatocyte-like
cells differentiated from human adipose derived stem
cells (hADSCs) in experimental models of hepatic injury
by carbon tetrachloride could express hepatic specific
genes, and possess the functional properties of mature
hepatocytes, including secretion of albumin, synthesis
of albumin (ALB) and cytochrome P450 enzyme activity.
iHeps could restore the liver function and prolong
survival. The results show a very important step towards
future establishment of an alternative and successful
therapy for autologous hepatocytes to treat liver disease.
Methods
Isolation, culture, and expansion of hADSCs
hADSCs were isolated from human female abdominal
adipose tissue obtained during Caesarean section. The
adipose tissue was washed with Hank’s balanced salt
solution (HBSS; Gibco). The washing step was repeated
until all blood vessels and connective tissues appeared to
have been liberated (usually three washes). The adipose
tissue sample was minced into small pieces and digested
in Dulbecco’s modified Eagle’s medium LG (DMEM-LG;
Gibco) containing 1 mg/mL (w/w) collagenase Type I,
and then incubated at 37 °C for 30 min with gentle shak-
ing at 120 rpm. After the addition of fetal bovine serum
(FBS; Gibco) to a final concentration of 10 % (v/v), the
solution was filtered through a 100-μm filter (BD
Falcon) to remove solid aggregates. The sample was sub-
sequently centrifuged at 1500 rpm for 5 min at 4 °C.
The pellet was washed twice with ice-cold HBSS and
centrifuged at 1500 rpm for 5 min. The supernatant was
removed and the cell pellet was resuspended in complete
medium (DMEM-LG with 15 % FBS and 1 % antibiotic
antimycotic solution) in a 75-cm2 culture dish and main-
tained in an incubator supplied with a humidified atmos-
phere of 5 % CO2 at 37 °C. After 2 days, non-adherent
cells were removed by two or three washes with HBSS
and adherent cells were further cultured in complete
medium. The medium was changed every 2 days until the
monolayer of adherent cells reached 80–90 % confluence.
Cell passaging was performed using a 0.25 % trypsin solu-
tion (Sigma-Aldrich). Approximately 3 × 105 cells were
used to inoculate a 75-cm2 culture dish and incubated at
37 °C and 5 % CO2.
Primary human hepatocyte isolation
Liver specimens were obtained from the margin of the
macroscopically tumor-free liver tissue immediately after
resection. Samples were taken under sterile conditions,
transferred into ice cold (4 °C) William’s E medium, and
human primary hepatocytes were immediately isolated
under sterile conditions using collagenase. The liver
specimen was washed twice with ice-cold HBSS. The
washing step was repeated until all blood vessels and
connective tissues appeared to have been liberated (usu-
ally three washes). The specimens were then cut into
small pieces and digested with William’s E medium con-
taining IV collagenase, and incubated at 37 °C for 30 min
with gentle shaking at 120 rpm. After the completion of
digestion, a final concentration of 10 % (v/v) FBS was
added to stop the collagenase reaction. The resulting cell
suspension was filtered through a 100-μm filter (BD
Falcon) for the removal of solid aggregates. The filtered
sample was subsequently centrifuged at 1500 rpm for 5
min at 4 °C. Finally, the cell pellets were washed with
HBSS followed by another centrifugation (1500 rpm for
5 min at 4 °C).
Flow cytometry analysis
For flow cytometry detection of surface antigens,
hADSCs (1 × 106 cells) were washed and resuspended in
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stain buffer (PBS; BD Biosciences) containing saturating
concentrations (1:100 dilution) of the following conju-
gated mouse or rat monoclonal antibodies against human
antigens (Biolegend) for 30 min in the dark at 2–8 °C:
CD105-FITC, CD90-FITC, CD44-FITC, CD31-APC,
CD34-PE, CD29-PE, CD45-PerCP/cy5.5, CD166-PE,
HLA-DR-PE and FITC-CD90, CD105 labeled mouse
IgG1k Isotype control, FITC-CD44 labeled Rat IgG2b k
Isotype control, PerCP/cy5.5-CD45 labeled mouse IgG1 k
Isotype control, APC-CD31 labeled mouse IgG1 k Isotype
control, PE-CD29, 166 labeled mouse IgG1 k Isotype con-
trol, and PE-HLA-DR labeled Mouse IgG2a k Isotype
control.
For intracellular staining of ALB and alpha-1-
antitrypsin (AAT), 5 × 105 iHeps were harvested and
fixed with 4 % paraformaldehyde for 30 min, and then
permeabilized in staining buffer (BD) for 10 min. Cells
were then incubated with primary antibody (Goat anti-
human Albumin, Bethyl; Mouse anti-human AAT,
Thermo) in staining buffer overnight at 4 °C, followed
by secondary antibody (dylight 488 conjugated Donkey
anti-goat IgG, Bethyl; dylight 594 conjugated Donkey
anti-mouse IgG, Bethyl) incubation for 1 h at 37 °C. The
cell suspensions were washed twice and resuspended in
300–500 μL PBS for flow cytometry (FACS Aria, BD
Biosciences) using FLOWJO TM software (TreeStar,
Inc., Ashland, OR, USA).
Adipogenic differentiation
Passage 3 hADSCs were counted and seeded at a density
of 105 per well in a six-well plate. When the cells
reached 100 % confluence, Adipogenic Differentiation
Basal Medium A supplemented with 10 % FBS, 1 %
penicillin-streptomycin, dexamethasone, isobutylmethyl-
xanthine (IBMX), insulin, glutamine, and Rosiglitazone
(Cyagen Biosciences) was added to four wells and
complete culture medium (DMEM-LG) was added to
other two wells as the negative controls. Three days later
the medium was changed to hADSC Adipogenic Differ-
entiation Basal Medium B, which contains 10 % FBS,
dexamethasone, insulin, and glutamine (Cyagen Biosci-
ences). The medium was changed 24 h later to medium
A. Medium A and B were alternated 3–5 times (12–20
days), and then medium B was maintained for 4–7 days
until the lipid droplets were big and round enough. Dur-
ing maintained culture, medium B was changed every
2–3 days with fresh medium B. Oil red O staining
assessed the differentiation potential of adipogenesis for-
mation of intracellular lipid droplets.
Osteogenic differentiation
Passage 3 hADSCs were harvested by trypsin digestion
as described above; the cells were counted and seeded at
a density of 105 per well in a six-well plate. When the
cells reached 100 % confluence, MSC Osteogenic Differen-
tiation Basal Medium containing 10 % FBS, 1 % penicillin-
streptomycin, glutamine, ascorbate, β-glycerophosphate,
and dexamethasone (Cyagen Biosciences) was added to
four wells while complete culture medium was added to
the other two wells as the negative controls. The medium
was changed every 3 days for 3 weeks. The differentiation
potential for osteogenesis was assessed by 40 mM Alizarin
Red (pH 4.2) staining.
Chondrogenic differentiation
Passage 3 hADSCs were counted and seeded at a density
of 106 per well in an ultra-low attachment six-well plate.
When the pellet cultures contained 2.5 × 105 hADSCs,
MSC Chondrogenic Differentiation Basal Medium,
which consists of dexamethasone, ascorbate, sodium
pyruvate, proline, TGF-β3, and insulin-transferrin-
selenium (ITS; Cyagen Biosciences), was added to four
wells and complete culture medium was added to the
other two well as the negative controls. The medium
was replaced every 3 days for 3 weeks. The differenti-
ation potential for chondrogenesis was measured by
Alcian blue staining.
Hepatic differentiation of hADSCs in vitro
hADSCs between passage 3 and 7 were planted at a
density of 2–3 × 104 cells/cm2 on collagen I-coated
dishes (Invitrogen) and cultured in expansion medium at
37 °C with 5 % CO2. Once the cells reached 100% con-
fluence, they were incubated with 10 % FBS RPMI-1640
(Gibco) medium containing 1 μM ATRA for 24 h. The
cells were then incubated with serum-free RPMI-1640
medium containing 100 nM IDE1, 3 μM CHIR99021,
and 10 μM LY294002 (Selleckchem) for 24 h. Next, the
cells were then incubated with serum-free RPMI-1640
medium containing 100 nM IDE1, 10 μM LY294002,
250 nM LDN-193189, and 20 ng/mL FGF4 (PeproTech)
for 2 days and then changed to serum-free RPMI-1640
medium containing 100 nM IDE1, 10 μM LY294002,
and 20 ng/mL FGF4 for 24 h. The medium was changed
to Williams’ E (Gibco) supplemented with 150 ng/mL
hepatocyte growth factor (HGF; Sino Biological), 20 ng/
mL FGF4, 30 ng/mL oncostatin M (OsM; PeproTech),
2 × 10−5 mol/L dexamethasone (Dex, Sigma-Aldrich),
and 1% ITS (Sigma-Aldrich). The differentiation medium
was changed every 2 days.
Immunofluorescence
For immunofluorescent staining, the cells were fixed
with 4 % paraformaldehyde for 15 min at room
temperature, and then incubated with PBS containing
0.1 % Triton X-100 (Sigma-Aldrich) for 15 min. Cells
were then washed three times with PBS. After being
blocked by 5 % BSA in PBS for 1 h at room temperature,
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cells were incubated with primary antibodies at 4 °C
overnight, washed three times with PBS, and then incu-
bated with appropriate fluorescence-conjugated second-
ary antibody for 1 h at room temperature in the dark.
Nuclei were stained with DAPI (Sigma-Aldrich). Primary
and secondary antibodies were diluted in PBS containing
3 % BSA. Antibodies used for immunofluorescence were
as follows: Goat anti-human Albumin (Bethyl, 1:200),
Mouse anti-human AAT (Thermo, 1:40), dylight 488
conjugated Donkey anti-goat IgG (Bethyl, 1:200), dylight
594 conjugated Donkey anti-mouse IgG (Bethyl, 1:200),
Rabbit anti-human AFP (Santa, 1:500), Mouse anti-
human FOXA2 (Abcam, 1:250), Mouse anti-human hep-
atocyte (HepPar1) (Gene Tech, 1:20).
Reverse transcription-polymerase chain reaction (RT-PCR)
RNA (1 μg) was reverse transcribed into cDNA with the
M-MLV Reverse Transcriptase (Promega) according to
the manufacturer’s instructions. PCR was performed
with HiFi Taq polymerase (TransGen). On completion
of the PCR, products were examined on 1 % agarose gel.
β-actin primers were used as an internal standard and
amplifications of products were performed at 30 cycles.
Primer sequences are provided in Table 1.
Real-time quantitative PCR
Total RNA was isolated from hADSCs, iHeps, and pri-
mary human hepatocytes (PHH) using the Trizol Re-
agent (Sigma-Aldrich). Quantitative real-time PCR was
performed with SYBR Premix Ex Taq (TaKaRa) on the
ABI StepOnePlus real-time PCR system (Applied Biosys-
tems). All quantitative PCR data were obtained with at
least two repeats. The PCR products were confirmed by
proper melting curves. β-actin primers were used as an
internal standard and amplifications of products were
performed at 39 cycles. Primer sequences are provided
in Table 2.
Western blot analysis
Western blotting was used to detect the presence of
CK18, HNF4α, AFP, ALB, and AAT in iHeps. The cells
were dissolved in the Mammalian Protein Extraction Re-
agent (Pierce, Rockford, IL, USA). Proteins were sepa-
rated on an SDS-polyacrylamide gel and transferred to
PVDF (polyvinylidine difluoride) membranes (BIORAD,
Tokyo, Japan). Blots were saturated with 5 % skimmed
milk in TBS-T for 1 h at room temperature, and after-
wards incubated overnight with anti-human mouse
monoclonal CK18 (Santa Cruz Biotechnology, Inc., CA,
USA), rabbit polyclonal HNF4α (Santa Cruz Biotechnology,
Inc.), rabbit polyclonal AFP (Santa Cruz Biotechnology,
Inc.), mouse polyclonal ALB (Santa Cruz Biotechnology,
Inc.), and rabbit polyclonal AAT (Abcam). Following wash-
ing in TBS-T, the membranes were incubated for 30 min
with sheep anti-rabbit or anti-mouse IgG-HRP-linked
whole antibodies (GE Healthcare Bio-Sciences KK, Tokyo,
Japan). Monoclonal antibodies against human GAPDH
were used as a control of protein loading (Protein Tech).
Periodic acid-schiff (PAS) staining
After 4 % paraformaldehyde fixation, cells were incu-
bated for 5 min in 1 % periodic acid (Sigma, St. Louis,
MO, USA) and washed with distilled water prior to in-
cubation with Schiff ’s reagent (Sigma) for 15 min. After
a 5-min wash in tap water, cells were washed and visual-
ized under a light microscope (CKX41; Olympus, Japan).
Indocyanine green and Oil Red O staining
For indocyanine green (ICG; Sigma-Aldrich) uptake
assay, cells were changed to a medium with 1 mg/mL
ICG and incubated at 37 °C for 1 h, followed by washing
with PBS three times. For Oil red O staining, confluent
cells were cultured in hepatic differentiation medium.
After 10 days, cells were washed twice with PBS, fixed in
Table 1 Forward (F) and reverse (R) primer pairs used for
polymerase chain reactions to detect hepatic specific gene
transcripts in human adipose-derived stem cells, induced
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4 % formalin for 30 min, washed with PBS twice,
followed by Oil Red O (Sigma-Aldrich) staining for 10
min, and then washed twice with 70 % ethanol and visu-
alized under a light microscope (CKX41; Olympus).
Uptake of low-density lipoprotein assay
The uptake of low-density lipoprotein (LDL) was de-
tected with the Dil-Ac-LDL staining kit (Biomedical
Technologies, Stoughton, MA, USA). The assay was per-
formed according to the manufacturer’s instructions.
Briefly, cells were incubated in serum-free DMEM-LG
containing 10 μg/mL 1,1′-dioctadecyl-3,3,3′,3′-tetra-
methy-lindocarbocyanine perchlorate acetylated-LDL
(Dil-Ac-LDL) for 4 h at 37 °C. Cells were then washed
and visualized under a fluorescence microscope (BX51;
Olympus).
Albumin and alpha-1-antitrypsin ELISA
To determine the secretion of human ALB and AAT, su-
pernatants of the cell culture were collected at different
time points. For transplantation experiments, animal
serum was collected. Levels of human ALB and AAT
were measured by the human Albumin ELISA kit
(Bethyl Laboratory) and the human α-1-antitrypsin
ELISA kit (Bethyl Laboratory) according to the manufac-
turer’s instructions. Serum was diluted in a range from
10- to 10,000-fold to obtain values falling within the lin-
ear range of the standard curve.
Mice
The genetic background of the NPG mice (Beijing Vital-
star Biotechnology Co., Ltd.) was NOD-PrkdcscidIL2rgnull.
For non-obese diabetes (NOD) mice, the phagocytic func-
tion of the macrophage for human cells was weak and the
innate immune systems, such as the complement system
and dendritic cell function, was significantly decreased.
The Prkdcscid:Prkdc (protein kinase DNA-activated
catalytic) gene mutation brings about the loss of T cells
and B cells, which causes the severe combined immuno-
deficiency in both cellular and humoral immunity in mice
(severe combined immune deficiency (SCID)). The IL2rgnull
(interleukin-2 receptor gamma chain (IL-2Rγc), also known
as CD132) is the common receptor subunit of cytokines,
such as IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21, which has
an important immune function. The mice immune func-
tion was severely reduced after knockout of this gene, the
activity of natural killer (NK) cells was especially almost
lost. All animal experiments were performed in accordance
with institutional animal regulations.
iHep transplantation to CCl4-induced acute liver failure
mice
NPG mice were injected with CCl4 (Sigma-Aldrich) at a
dose of 0.5 mL/kg body weight by intraperitoneal injec-
tion. Eight hours after CCl4 treatment, hADSCs and
iHeps (1 × 106 cells/animal, 300 μL) were intravenously
injected into the mice. Meanwhile, control animals
received an equal volume of PBS. Blood and liver
samples were collected after the surviving animals were
sacrificed. Blood samples were used for blood biochem-
ical analysis. Livers of recipient mice were embedded in
Tissue Freezing Medium (Leica) and then frozen in
liquid nitrogen. Cryostat sections (8 μm) were stained.
Results
Identification and characterization of hADSCs
The cells isolated from the abdominal fat tissue of
healthy women, and the cultures were observed using an
inverted light microscope. The attachment of spindle-
shaped cells to the culture dish was observed after 1 day
of culture. Primary cultures reached 80–90 % confluence
in approximately 4–5 days. During the passaging, the
cell growth tended to accelerate and the morphology of
the cells changed gradually. After three passages, the
cultures showed homogenous fibroblastic morphology
and, at ten passages, the cell morphology did not change
(Fig. 1a). hADSCs expressed the surface marker profile
typical for MSCs using flow cytometry. The cells were
positive for the mesenchymal markers CD29, CD44,
CD166, CD105, and CD90, and negative for hematopoietic
and endothelial markers CD34, CD45, and CD31. They also
had low immunogenicity, and low or almost no expression
of HLA-DR. As shown in Fig. 1b, under adipogenic,
Table 2 Forward (F) and reverse (R) primer pairs used for
polymerase chain reactions to detect hepatic specific gene
transcripts in human adipose-derived stem cells, induced
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osteogenic, and chondrogenic differentiation conditions
the cells were able to differentiate into osteocytes, con-
firmed by Alizarin Red staining (Fig. 1c). They were also
able to differentiate into adipose cells, verified by Oil red
O staining (Fig. 1d). Furthermore, they could differentiate
into chondrocytes, identified by Alcian blue binding assay
(Fig. 1e). The results showed that we isolated high purity
hADSCs which exhibited typical characteristics of MSCs
and had good pluripotent differentiation potential.
Induction of hADSCs into iHeps in vitro
We applied a three-step protocol (described in
Methods) and to induce hepatic differentiation of
hADSCs (Fig. 2a). In this protocol, hADSCs were
allowed to reach approximately 100 % confluence on
collagen type I-coated dishes. The cell morphology is
shown in Fig. 2b (panel I). These were then treated
with ATRA for 24 h, followed by treating with endo-
dermal induction medium in the presence of IDE1,
CHIR99021, and LY294002. After 24 h, the cell
morphology had changed into a short spindle shape
from that of a long spindle shape (Fig. 2b, panel II).
Following the endodermal induction step, cells were
treated with the hepatogenic induction medium for 3
days, which changed the cell morphology from a spindle
shape to a polygonal shape (Fig. 2b, panel III). Immuno-
fluorescent staining revealed that some of the cells were
positive for the endoderm marker FOXA2 (Fig. 2c) and
early liver cell marker AFP (Fig. 2d), indicating that the
hADSCs differentiated into hepatic precursor cells.
Finally, the medium was changed to maturation
medium, which resulted in cell morphology changing
into the typical cuboidal shape of primary hepatocytes
that had tight cell-cell contact (Fig. 2b, panel IV). In
brief, over a period of 10 days of culture, cell morph-
ology changed from a spindle to a rather polygonal
shape typically associated with adult hepatocytes.
Linked with this transformation, the expression of
cytokeratin (CK)18, an intermediary filament protein
predominantly expressed in epithelial cells, was upregu-
lated as demonstrated by RT-PCR and Western blot
analysis (Fig. 2e, f ), which showed that hADSCs trans-
formed into epithelial cells from mesenchymal cells.
The hepatocytic phenotype of the cells was further sub-
stantiated by the appearance of functional in vitro
markers barely expressed in undifferentiated cells. By 10
days post-induction, differentiated cells expressed genes
specific for mature hepatocytes and these genes
increased gradually during hepatic induction, suggesting
that hepatogenic differentiation is a progressively coor-
dinated process. In contrast, CK19 and CK7 were
upregulated within 5 days of culture, slowly diminishing
or disappearing thereafter (Fig. 2e, f ). These results indi-
cated that our induction system mainly directed hADSC
differentiation into hepatocytes rather than to cholan-
giocytes. In other words, we had successfully obtained
hADSC-derived induced hepatocytes using a new non-
transgenic protocol.
Fig. 1 Characterization of human adipose-derived stem cells (hADSCs). a Image of primary hADSCs, passage (P)5 hADSCs, and passage 10
hADSCs. The cells showed homogenous fibroblastic morphology. b Expression of cell surface markers on hADSCs. hADSCs possessed the surface
marker profile typical for mesenchymal stem cells, and were positive for the mesenchymal markers CD29, CD44, CD166, CD105, and CD90, and
negative for the hematopoietic and endothelial markers CD45, CD34, and CD31), and showed almost no expression of HLA-DR. c–e Multiple
differentiation potential of hADSCs. Under specific induction conditions, they could differentiate into adipose cells (d) osteocytes (c), and chondrocytes
(e). Scale bars = 250 μm (a, P0), 100 μm (a-P5, P10, c, d, e)
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iHeps assumed functional attributes of mature
hepatocytes
We measured the secretion of human ALB, AAT, glyco-
gen synthesis, Dil-ac-LDL, ICG uptake and the metab-
olism of lipoid, and CYP enzyme activity to test
whether iHeps derived from hADSCs assumed the
functional attributes of mature hepatocytes. The ALB
and AAT synthesis assay is a specific test for the pres-
ence and metabolic activity of mature hepatocytes. Ap-
proximately 25 % of cells expressed both ALB and AAT
at day 10 as determined by immunofluorescent staining
and flow cytometry (Fig. 3a, b), indicating that the
iHeps possessed the capacity to produce albumin and
alpha-1 antitrypsin. To assess the metabolic activity of
iHeps we quantified ALB and AAT secretion. We found
that iHeps had a remarkable capacity for secreting the
plasma proteins ALB and AAT, which gradually
increased in the iHep culture system during the hepato-
genic induction period (Fig. 3c, d). iHeps also displayed
numerous hallmark functions of mature hepatocytes,
such as metabolism of lipoid, glycogen storage, acety-
lated low-density lipoprotein (ac-LDL) intake, and ICG
uptake (Fig. 3e–h). The drug metabolic capacity is one
of the most important functions that distinguish hepa-
tocytes. Cytochrome P450 (CYP450) enzymes of hepa-
tocytes are the main enzymes accounting for drug
metabolism. Their activity is used to evaluate drug me-
tabolism of hepatocytes. We quantitatively confirmed
the expression of the CYP enzymes CYP1A1, CYP1A2,
CYP2A6, CYP2C9, CYP2B6, CYP2D6, and CYP3A4 in
iHeps. The results showed that iHeps already expressed
these genes at remarkable levels (Fig. 3i). These results
offer the possibility of using iHeps for toxicity screening
during drug discovery.
Fig. 2 Induction protocols to generate iHeps from human adipose-derived stem cells (hADSCs). a Schematic diagram of hADSC differentiation
into iHeps. b The sequential morphological changes from hADSCs to iHeps; I Cell morphology before hepatic induction; II The change of cell
morphology with a short spindle shape after 1 day culture in the phase I induction medium; III At day 5, the cell morphology had become polygonal
in shape; IV The morphology of hepatocyte-like cells (iHeps). c, d Immunostaining revealed the vast majority of induced cells were positive for the
endoderm marker FoxA2 and early hepatocytes marker AFP at the fifth day (upper right: hADSCs). e Gradually increased hepatic gene expression and
slowly diminishing or disappearing billiard gene expression during the induction of iHeps. The expression levels of the indicated genes were analyzed
by RT-PCR. f Western blot analysis indicated that C18 (45 kDa), AFP (69 kDa), HNF4a (54 kDa), ALB (66 kDa), and AAT (57 kDa) were actively synthesized
in hADSC-derived hepatocytes; GAPDH was used as an internal control (35 kDa). Scale bars = 100 µm (b) and 25 µm (c, d). PHH primary human
hepatocyte; ATRA All trans retinoic acid
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Fig. 3 (See legend on next page.)
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Therapy potential of iHeps in CCl4-induced acute
fulminant liver failure
We used serial transplantation to investigate whether
iHeps could have sufficient hepatic functions to support
the liver in recovering from acute fulminant hepatic in-
jury. NPG mice were injected with CCl4 to trigger acute
fulminant hepatic injury; 8 h later, intravenous trans-
plantation of either differentiated hepatocytes or undif-
ferentiated hADSCs (1 × 106 cells/animal, 300 μL), or an
equal volume of PBS into control animals, was per-
formed (Fig. 4a). The group transplanted with PBS all
died within 24 h; 7 days after the injection of CCl4, 1 of
5 recipient mice survived after transplantation with
hADSCs (survival rate 20 %) and 3 of 5 mice receiving
iHep transplantation survived (survival rate 60 %). The
Kaplan-Meier survival curve is depicted in Fig. 4b.
Transaminase activity was measured and, 7 days after
CCl4 treatment, the mice receiving iHep transplantation
showed nearly normal levels of serum glutamic-pyruvic
transaminase (ALT) and glutamic oxalacetic transamin-
ase (AST) (Fig. 4c and d). ELISA analysis of human-
specific albumin antibody showed repopulation of iHeps
in the liver parenchyma in the surviving mice which
could secret human ALB (Fig. 4e). Histological analysis
revealed that iHeps significantly improved recovery from
CCl4-induced liver damage (Fig. 4f, g). Immunofluores-
cence staining of human HepPar1 showed that iHeps
repopulated the liver parenchyma in the surviving mice.
Repopulated cells were positively stained by HepPar1, an
antibody specifically labeling human hepatocytes, but
not mouse hepatocytes or non-hepatic cells (Fig. 4h).
Engraftment of iHeps in recipient livers was further con-
firmed by genomic PCR for human-specific Alu DNA
sequences (Fig. 4i), and showed that repopulated iHeps
were micro-detected in the NPG mice liver and replaced
necrotic hepatocytes to restore liver function. Therefore,
we can conclude that, under normal conditions, the sur-
viving mice are capable of long-term survival. Together,
this indicates that iHeps may have potential clinical ap-
plication as a treatment for acute liver injury.
Discussion
MSCs have great potential for clinical application in
regenerative medicine. Adipose tissue is an important
source of MSCs. A sufficient number of stem cells (that
is, hADSCs) can be easily obtained with minimal
invasion from a patient’s own adipose tissue, and
hADSCs can be easily isolated and cultured in vitro.
hADSCs have a broader differentiation potential and can
differentiate into all mesodermal lineage cells, including
adipocytes, osteocytes, and chondrocytes. However, they
do not express hematopoietic cell or endothelial cell anti-
gens, and also have low immunogenicity. Unfortunately,
the subsequent interaction of transplanted undifferenti-
ated ADSCs with liver parenchyma cells in the context of
fibrosis, cancer, or liver dysfunction and whether they pro-
mote the development of these symptoms is still un-
known. Moreover, recent studies demonstrated long-term
engraftment of MSC-derived hepatocyte-like cells in a
xenogeneic transplantation model of liver regeneration.
Engraftment was significantly improved using MSCs pre-
differentiated to hepatocyte-like cells in vitro as compared
to undifferentiated MSCs [16]. Therefore, we transplanted
hepatocyte-like cells differentiated from ADSCs to treat
acute fulminant hepatic injury. Several studies have de-
scribed the differentiation of hADSCs into cells that dis-
play hepatic characteristics [16–22]. However, those in
vitro differentiation methods are not applicable to a prac-
tical and clinical use, as about 1 month is required to in-
duce hADSCs into cells with hepatic functions and using
viral vector-integrated TFs (Transcription factors) to re-
program hADSCs into hepatocytes has substantial safety
problems. Clinical applications in the future will require a
special approach, such as shortening and making as safe
as possible ex vivo manipulations, including cultivation
and direct hepatic fate. In the present study, we developed
a novel non-transgenic protocol that rapidly generated
functional hepatocytes from hADSCs within a very short
time. Ten days is sufficient to generate in vitro cells which
show hepatocyte specific morphology and functionality.
To our knowledge, this is the first time such a short hepa-
togenic differentiation protocol has been presented.
For specific tissue-derived stem cells, such as adi-
pose tissue-derived MSCs, when differentiating into
hepatocytes, induction of various tissues isolated from
specific stem cells and even embryonic stem cells into
specific endodermal cells, become a key step towards
producing hepatocytes [23–25]. The nodal signaling
pathway and other important signaling pathways play
a major role in this process, including Wnt, PI3K(–),
FGF, and BMP signaling pathways. In the processes of
cell culture, there are many different combinations of
(See figure on previous page.)
Fig. 3 Characterization of induced hepatocytes (iHeps) in vitro. a Immunofluorescence analysis of albumin (ALB) and alpha-1 antitrypsin (AAT) in
iHeps. Most iHeps expressed both ALB and AAT at the tenth day. b iHeps were stained for ALB and AAT at 10 days after induction. ALB and AAT
double-positive cells, as quantified by flow cytometry, were used to determine the conversion efficiency of iHeps. c, d Secretion of ALB and AAT
increased during the hepatogenic induction period as measured by ELISA. e–h Analysis of basic hepatic function in iHeps, including Oil-Red-O
staining (e), PAS staining (f), ICG intake (g), and LDL uptake (h). i The mRNA levels of CYP genes were determined by qPCR in human adipose-derived
stem cells (hADSCs), iHeps, and primary human hepatocytes (PHH). Data are normalized to β-actin. Scale bars = 100 μm (a, e, f, g), 50 μm (h)
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cytokines that regulate these signaling pathways which
may give us the opportunity to induce the desired
endoderm cells. When inducing the endoderm cells
into hepatocytes, the activin/nodal pathway needs to
be suppressed, but the Wnt signaling pathway still
plays an important role, although it does not require
to be exogenously added because definitive endoderm
cells abundantly expressed wnt3a [26–28]. In our
study, during the endodermal induction step, hADSCs
are exposed to a high level of activin/nodal (IDE1),
Wnt (CHIR99021), and PI3K(-) (LY294002) signals
that are designed to mimic events during embryonic
Fig. 4 The therapeutic effects of induced hepatocytes (iHeps) on acute liver failure. a Schematic diagram of cell transplantation into the livers of
NPG mice. NPG mice were intraperitoneally injected with carbon tetrachloride (CCl4) to trigger fulminant hepatic injury. Eight hours after
CCl4 treatment, human adipose-derived stem cells (hADSCs) and iHeps (1 × 106 cells/animal, 300μL) were intravenously injected into the mice
and control animals received equal volume of phosphate-buffered saline (PBS). b Kaplan-Meier survival curve of NPG mice with acute liver failure.
c, d Serum levels of glutamic-pyruvic transaminase (ALT) (c) and glutamic oxalacetic transaminase (AST) (d) in CCl4-treated mice before (day 0 (d0))
and after (d7) transplantation of hADSCs or iHeps. e Serum levels of human albumin (ALB) before (d0) and after (d7) transplantation of hADSCs or
iHeps. The albumin antibody is human specific. f, g Livers in CCl4-treated mice 8 h later; PBS, hADSCs, and iHeps were intravenously injected into
the mice. Macroscopic images of freshly isolated livers (f) and hematoxylin and eosin staining of liver sections (g) are shown after treatment. The
liver has already recovered from hepatitis by the seventh day. Arrows represent CCl4-induced hepatitis and hemorrhage in the liver. h The integration of
iHeps in mice livers was determined by immunostaining for human HepPar1 in serial sections. i Human-specific Alu sequences were analyzed by PCR
using genomic DNA extracted from iHep-repopulated mice livers. Scale bars = 5 mm (f) and 100 μm (g, h). Data are presented as mean ± SD
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development in order to allow definitive endoderm
(DE) formation. IDE1 is a small molecule compound
and could induce DE differentiation in up to 50 % of
hESCs (or 80 % of mESCs) in the absence of activin
A (a typically used DE inducer) [29–32]. During the
hepatocyte precursor induction step, we used the
cytokines and small molecules which generally start
the original intestinal development, such as Wnt
(endogenous), activin/nodal (IDE1), BMPs(–) (LDN193189),
PI3K(–) (LY294002), and FGF4. In the same way, during the
mature hepatocyte induction step, the common cytokines
such as FGF4, HGF, OSM, and Dex also simulate the devel-
opment of the process. Lysophosphatidic acid (LPA) is a
multi-function glycerophospholipid which activates β-
catenin signaling in stem cells and could be critical for
hepatocyte differentiation and survival. It would be interest-
ing to test if LPA added to our induction system could pro-
mote generation of iHeps or initiate their self-renewal in
vitro. It also would be very useful as iHeps genetically engi-
neered with stable β-catenin may reduce the number of
hepatocytes needed for cell transplant therapy and thus
eliminate the need for serial transplants [33–35].
In conclusion, our three-step differentiation protocol
was capable of inducing hADSCs into hepatocyte-like
cells (iHeps) in vitro, which co-expressed ALB and
AAT at a high level at the tenth day. iHeps also dis-
played other functions of mature hepatocytes, such as
glycogen storage, ac-LDL, and ICG uptake. Addition-
ally, transplanted iHeps could repopulate livers of
mice with acute fulminant liver failure, and restore
the liver function. Taken together, these results
showed that hADSCs may be a good candidate as
well as being ready available from patients’ autologous
adipose tissue to treat liver disease. Using the induced
hepatocytes (iHeps) as a source of hepatocytes should
help the development of alternative methods that may
supersede liver transplantation in patients with liver
failure. Therefore, hADSCs may be a superior choice
for the establishment of a therapy for the injured
liver. The possibility for their future autologous trans-
plantation application in the therapy of liver diseases
is very promising.
Conclusions
This present study isolated highly purified hADSCs
and provided a new, non-transgenic protocol to induce
hADSCs into functional hepatocyte-like cells within 10
days. The results show a very important step towards
the future establishment of an alternative and success-
ful therapy using autologous hepatocytes to treat liver
disease.
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